2:43 PM
 | 
Oct 27, 2017
 |  BC Week In Review  |  Company News  |  Deals

Arcturus, JNJ to develop nucleic acids to treat HBV

2:43 PM
Oct 27, 2017
by Allison Johnson
Text Size A A A
Print Print
PDF PDF

Arcturus Therapeutics Inc. (San Diego, Calif.) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize nucleic acid-based compounds to treat HBV. The companies will use Arcturus' unlocked nucleomonomer agent (UNA) Oligomer chemistry and LUNAR lipid-mediated delivery...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review
Sign Up

Article Purchase

$35 USD
More Info >